Late Onset Pompe Disease clinical trials

Explore recruiting late onset pompe disease clinical trials.

Recruiting late onset pompe disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Late Onset Pompe Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A French multicenter Phase 4 open label extension study of long-term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France

France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease

Germany, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease

Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.

Belgium, Germany, Denmark, France, Italy, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease

Slovenia, France, Italy, Belgium, Poland, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults with Late-Onset Pompe Disease

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Late Onset Pompe Disease trials by city

Late Onset Pompe Disease in Toronto Late Onset Pompe Disease in Vancouver Late Onset Pompe Disease in Montreal Late Onset Pompe Disease in Calgary Late Onset Pompe Disease in Edmonton Late Onset Pompe Disease in Ottawa Late Onset Pompe Disease in Winnipeg Late Onset Pompe Disease in Quebec City Late Onset Pompe Disease in Hamilton Late Onset Pompe Disease in Kitchener Late Onset Pompe Disease in London Late Onset Pompe Disease in Halifax Late Onset Pompe Disease in New York Late Onset Pompe Disease in Los Angeles Late Onset Pompe Disease in Chicago Late Onset Pompe Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease